ENVALITH
日本光電工業株式会社 logo

NIHON KOHDEN CORPORATION

6849・Prime Market・Electric Appliances

Official website
日本光電工業株式会社 logo
NIHON KOHDEN CORPORATION6849

Business

Nihon Kohden Corporation is a specialized medical electronic equipment manufacturer founded in 1951, with core products including Biological Measurement Equipment (electroencephalographs, electrocardiographs, etc.), Patient Monitor (bedside monitors, clinical information systems, etc.), and Therapeutic Equipment (defibrillators, AEDs, Ventilators, etc.). The group consists of 38 companies in total, comprising the Company and 37 consolidated subsidiaries, and operates in three segments: Japan, North America, and Other Regions (Europe, Asia, Latin America, etc.). Its main customers are medical institutions such as acute care hospitals, university hospitals, and clinics, and it has built a recurring revenue model combining equipment sales with consumables and maintenance services. Consolidated net sales for FY2026 (ending March 2026) were ¥235,099 million.

Business Model

The company builds its customer base through sales of equipment (biological measurement, patient monitors, therapeutic equipment), then generates ongoing revenue through consumables (electrodes, sensors, reagents, etc.) and maintenance services. In FY2026 (ending March 2026), consumables and services revenue reached ¥119,103 million (+6.2% year on year), exceeding equipment revenue of ¥115,996 million, functioning as a stable revenue base. Centered on a direct sales structure through 11 domestic branch offices and overseas local subsidiaries, the company is also expanding solutions businesses such as Digital Health Solutions (DHS).

Company Strengths

In FY2026 (ending March 2026), revenue from consumables and services reached ¥119,103 million (up 6.2% year on year), exceeding equipment sales of ¥115,996 million and accounting for more than half of total sales. Consumables and maintenance service revenue, based on ongoing transactional relationships with medical institutions, is less susceptible to economic fluctuations and contributes to stable cash flow generation.

The company operates manufacturing sites in Japan (Tsurugashima, Tomioka, and Kawamoto facilities), North America (Defibtech LLC and Nihon Kohden OrangeMed LLC), and Malaysia and China (Shanghai), building a self-contained group structure covering everything from research and development to manufacturing, sales, and maintenance. Production output for FY2026 (ending March 2026) was ¥95,700 million (up 5.9% year on year). The Tsurugashima Production Center began operations in March 2026, enhancing production capacity.

In North America, the company expands into major IDN/GPO and DoD/VA markets through Nihon Kohden America LLC and Adtech Corporation, among others, achieving North America sales of ¥53,623 million (up 19.4% year on year) in FY2026 (ending March 2026) and returning to profitability. The company has also continued to expand its business foundation in emerging markets, including the establishment of a development subsidiary in India (Nihon Kohden Advanced Technology Center Co., Ltd.) and a sales subsidiary in Saudi Arabia (Nihon Kohden Arabia RHQ LLC).

ENVALITH's Perspective

Operating profit for FY2026 (ending March 2026) was ¥18,745 million (down 9.5% year on year), with operating margin declining to 8.0% from 9.2% in the previous fiscal year. The gap remains large relative to the operating margin target of 15% (projected operating profit of ¥23,500 million) set for the final year (FY2027, ending March 2027) of the mid-term management plan "BEACON 2030 Phase II." Increased SG&A expenses (¥102,981 million, up 6.8% year on year) stemming from wage increases, R&D investment, and rising M&A amortization costs are weighing on results, and improvement in gross profit margin through a shift to proprietary products following the discontinuation of Abbott products is the key to earnings recovery.

Ordinary profit for FY2026 (ending March 2026) increased to ¥22,544 million (up 10.7% year on year), but this was due to an external factor—a swing from a foreign exchange loss of ¥951 million in the previous fiscal year to a foreign exchange gain of ¥3,484 million. On an operating profit basis, the company posted a 9.5% year-on-year decline, indicating that core business profitability has weakened. Extraordinary losses included ¥2,429 million for early retirement incentive payments and other items, plus ¥850 million in losses related to retirement benefit plan revisions, reflecting that structural reform costs are being incurred upfront. For FY2027 (ending March 2027), operating profit is forecast to grow 25.4%, but the focus will be on the tug-of-war between this growth and the domestic revenue decline (high single digits) expected from the discontinuation of Abbott products (December 2026).

The cash conversion cycle for fiscal year 2025 stood at 215 days, exceeding the 190-day target by 25 days. This was mainly due to a temporary buildup of inventory in preparation for the launch of the PLM/MES system and the opening of the Tsurugashima Production Center, but the outlook for fiscal year 2026 calls for only a partial recovery to 195 days, given the need to secure component inventories amid Middle East tensions. Against the ROE target of 12% (for FY2027, ending March 2027), the actual result for FY2026 (ending March 2026) was 8.1%. Shareholder returns remain proactive, including share buybacks (3,135,900 shares, ¥4,999 million) and the planned retirement of 3 million shares (scheduled for June 2026), but the consolidated total return ratio of 70% (for the current fiscal year) is elevated, reflecting the low level of profit, underscoring that growth in core business profit is a prerequisite for improving capital efficiency.

Growth Strategy

Under BEACON 2030 Phase II, the company is pursuing North American growth, strengthening of product competitiveness, and profitability reform as a unified three-pronged approach

Deepening penetration in major IDN/GPO and DoD/VA markets while expanding sales of ventilators and the neurology group (including Ad-Tech Corporation) products. In FY2026 (ending March 2026), the North America segment turned profitable (profit of ¥2,858 million). For FY2027 (ending March 2026)*, North America sales are planned at ¥56,300 million (+13.0% year on year), also anticipating a recovery in Patient Monitor sales through DHS collaboration.

Strengthening the development and production framework through the PLM/MES system (operational from September and November 2025) and the Tsurugashima Production Center (operational from March 2026). Launching new products such as the Auto Shock AED, mid-range ventilator models, and SEEG electrodes, as well as bringing DHS products (on-site alarm analysis software, admission/discharge support software) to market.

Aiming to improve gross profit margin by scaling down locally sourced Abbott products following the termination of the Abbott product handling arrangement (December 2026) and focusing on sales of proprietary products. Also generating cost reduction effects through reduced overtime hours and restrained headcount growth via generative AI utilization, relocation and consolidation of domestic business sites, and review of internal IT contracts. The FY2027 (ending March 2027) operating margin target is forecast at 10.1% (¥23,500 million), against the final medium-term plan target of 15%.

Expanding the business foundation through the India development subsidiary (Nihon Kohden Advanced Technology Center Corporation, established September 2025), the Saudi Arabia sales subsidiary (Nihon Kohden Arabia RHQ LLC, operations commenced January 2026), and the consolidation of Dwell Corporation as a subsidiary (February 2026). Local production in India is scheduled to commence within FY2027 (ending March 2027).

Promoting the introduction of Nihon Kohden's proprietary ROIC framework and shortening of the cash conversion cycle (from 215 days in FY2025 to a target of 195 days in FY2026). Strengthening shareholder returns through share buybacks (¥4,999 million), retirement of 3 million shares (planned for June 2026), and a dividend increase (from ¥32 to a planned ¥33). Under the policy of a consolidated total payout ratio of 35% or more, the actual result for the current period was 70%.

Last updated: July 19, 2026